title: Eye on statins: A comprehensive review.
abstract: Over the last 25 years, statins have demonstrated their safety from an ophthalmologic standpoint. Studies relating statin to cataract formation are insufficient to alter the usual and customary prescription of statins. If there is an association between statins and cataracts, it is weak and clinically insignificant. Prospective studies have not demonstrated a benefit of adding statin therapy in patients with age-related macular degeneration (ARMD), but these studies have not been adequately powered to detect moderate differences. A subset of patients with persistently elevated lipids despite taking statins may be at higher risk of developing wet ARMD. The use of statins for the prevention and/ or treatment of glaucoma patients warrants further prospective study. There is a possibility that statins may unmask or exacerbate myasthenia gravis.
authors.affiliation: Mason Eye Institute, University of Missouri, USA. olsonea@health.missouri.edu
authors.forename: Evan A
authors.initials: EA
authors.lastname: Olson
authors.forename: Dean P
authors.initials: DP
authors.lastname: Hainsworth
authors.forename: Geetha
authors.initials: G
authors.lastname: Davis
authors.forename: John C
authors.initials: JC
authors.lastname: Hagan
mesh_terms: D002386:Cataract / Q000139:chemically induced / Q000517:prevention & control; D005901:Glaucoma / Q000517:prevention & control; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D008268:Macular Degeneration / Q000139:chemically induced; D009157:Myasthenia Gravis / Q000139:chemically induced
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors